|
This page last changed on 27.01.2015 by kkuk.
Link to EPIC Elderly cohort description
Contact persons for the cohort description
Bas Bueno-de-Mesquita and Jan van der Laan
Partner
Institute
RIVM - Rijksinstituut voor volksgezondheid en milieu (National Institute for Public Health and the Environment)
Key personnel for CHANCES
Responsible person:
Bas Bueno-de-Mesquita
Definition of the cohort
Target population
20-64 years old men and women recruited from the general population during 1993 - 1997 and residing in the 3 Dutch cities Amsterdam, Doetinchem and Maastricht
Recruitment
Doetinchem (D)
At baseline 7261 participants are selected inhabitants of the municipality of Doetinchem.
The majority of these (approx. 6100 participants) are also participating in the Doetinchem Cohort Study (Verschuren et al. 2008, Int J Epidemiol 2008; 37: 1236-1241).
Amsterdam and Maastricht (AM)
The other participants at baseline are selected inhabitants of Amsterdam (n=7283) and Maastricht (n=8110).
Years of recruitment
1993-1997
Size of the cohort
22.654 participants (total EPIC-Bilthoven) of which ~700 individuals in EPIC Elderly (criteria).
Recontacts
Period
1998-2002
Approach
Doetinchem (D)
These participants of the cohort have been invited to a re-examination (excluding those who emigrated, actively withdrew from the study or died).
Total number of Doetinchem participants in recontact 1: 4651. The response rate is approx. 75%.
Amsterdam and Maastricht (AM)
These participants have been recontacted by a Questionnaire.
Total number of Amsterdam & Maastricht participants in recontact 1: 10202. The response rate is approx. 66%.
Measurements at baseline and recontacts
| Socioeconomic |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Education |
Yes |
Yes (D) No (AM) |
| Income |
No |
No |
| Marital status |
Yes |
Yes |
| Occupation |
Yes, but uncoded |
Yes, but uncoded (D) No (AM) |
| Employment status |
Yes |
Yes (D) No (AM) |
| History of |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Diabetes |
Yes |
Yes |
| Dyslipidemia |
Yes |
Yes |
| Coronary heart disease |
Yes |
Yes |
| Stroke |
Yes |
Yes |
| Cancer |
Yes |
Yes |
| Benign neoplasms |
No |
No |
| Fracture |
No |
Yes |
| - Which site(s)? |
|
Hip, Other |
| Osteoporosis |
No |
No |
| Family history of |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Coronary heart disease |
Yes |
Yes (D) No (AM) |
| Stroke |
No |
No |
| Diabetes |
Yes |
Yes (D) No (AM) |
| Cancer |
Yes |
Yes (D) No (AM) |
| Lifestyle |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Current smoking |
Yes |
Yes |
| Past smoking |
Yes |
Yes |
| Alcohol use |
Yes |
Yes |
| Physical activity |
Yes |
Yes |
| Nutrition (yes/no) |
Yes |
No |
| - Number of food items available (approximately) |
150 |
|
| - Method(s) of dietary assessment (e.g. 24h-recall, food frequency questionnaire, dietary records) |
FFQ |
|
| - Supplement use |
Yes |
Yes |
| Anthropometry |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Weight and height |
Yes |
Yes |
| - Measured or self-reported |
Measured |
Measured (D) Self-reported (AM) |
| Unintended weight loss |
No |
No (D) Yes (AM) |
| Waist circumference |
Yes |
Yes (D) No (AM) |
| - Measured or self-reported |
Measured |
Measured (D) |
| Hip circumference |
Yes |
Yes (D) No (AM) |
| Measured or self-reported |
Measured |
Measured (D) |
| Blood pressure |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Measured blood pressure |
Yes |
Yes (D) No (AM) |
| History of hypertension |
Yes |
Yes |
| Blood tests |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Total cholesterol |
Yes |
Yes (D) No (AM) |
| HDL cholesterol |
Yes |
Yes (D) No (AM) |
| Triglycerides |
No |
No |
| - Fasting period |
|
|
| ApoA1 |
No |
No |
| ApoB |
No |
No |
| Glucose |
Yes |
Yes (D) No (AM) |
| - Fasting period |
Yes |
Yes (D) |
| Glucose tolerance test |
No |
No |
| HbA1c |
No |
No |
| GGT |
No |
No |
| CRP |
No |
No |
| 25-Hydroxy-Vitamin D |
No |
No |
| Other tests (specify) |
No |
No |
| Availability of frozen sera for further analysis |
Yes |
Yes (D) No (AM) |
- Storage temperature (°C) of sera
|
-196 |
-196 (D) |
| Availability of frozen plasma for further analysis |
Yes |
Yes (D) No (AM) |
- Storage temperature (°C) of plasma
|
-196 |
-196 (D) |
| Genetics |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Genotypic data |
No |
No |
| GWAS (specify) |
No |
No |
| Other high-throughput array data (specify) |
No |
No |
| Availability of DNA for further genotyping |
No |
No |
| Plated DNA |
|
|
| Otherwise stored DNA |
|
|
| Other measurements |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| Perceived health |
Yes |
Yes (D) No (AM) |
| Cognitive decline/dementia |
No |
No |
| Depression |
No |
No |
| Grip Strength |
No |
No |
| Lung function |
No |
No |
| Audiometry |
No |
No |
| Measurement of bone density (DEXA) |
No |
No |
| Quality of life instruments (such as SF-12, EUROQoL) |
No |
No |
| Limitations in ADL/IADL (i.e. Activities of daily living/Instrumental activities of daily living) |
No |
No |
| Multimorbidity instruments (such as CIRS-G) |
No |
No |
| Frailty scales |
No |
No |
| Reproductive history (for women) |
Yes |
Yes |
| Menstruation and menopausal status |
Yes |
Yes |
| Fertility problems |
No |
No |
| Pregnancies |
Yes |
Yes |
| Breast feeding |
Yes |
Yes (D) No (AM) |
| Hysterectomy and ovariectomy |
Yes |
Yes |
| History of oral contraceptive use |
Yes |
Yes |
| History of menopausal hormones use |
Yes |
Yes |
| Current use of exogenous hormones |
No |
No |
| Use of drugs |
Yes, but only for high blood pressure, high cholesterol and diabetes and at the time of blood draw, but uncoded. |
Yes, but only for high blood pressure, high cholesterol and diabetes and at the time of blood draw, but uncoded (D). No (AM) |
| Availability of classification of drugs, specify (e.g. Anatomical Therapeutic Chemical(ATC) classification system) |
No |
No |
| Additional Topics |
Baseline |
Recontact 1 (D=Doetinchem, AM=Amsterdam and Maastricht) |
| |
Headache |
|
| |
Chronic respiratory conditions |
|
Future recontacts
Re-assessement by questionnaire of participants in Amsterdam and Maastricht has been completed in 2011, a complete re-examination in Doetinchem in 2012, and a next round of follow-up is being planned in 2013 in all 3 centers.
Other follow-up
LMR, LKR, CBS and validation of cases of T2D, Parkinson, Inflammatory Bowel diseases, and in 2012 Rheumatoid Arthritis
It is anticipated that in many cohorts various follow-up end-points are measured during re-contact of the subjects. The availability of such follow-up data are covered above. In this section you should describe here any other means of follow-up, such as linkage to routine registers or review of hospital records for potential end-point events suggested by the re-contacts.
Follow-up period
Describe here the follow-up period. E.g. "10 years from the baseline examination" or "Up to the end of year 2008".
Sources of data
List here the sources of information on which the follow-up was based. E.g. "Death certificates obtained from ....", "Regional computerized hospital discharge register, which covers....", "Re-contact questionnaire".
Follow-up procedure
Describe here the follow-up procedure. E.g. "Record linkage to the national Causes of Death Register, using the unique personal identification code in use in the country", "Hospital records of the persons who indicated hospitalizations in the re-examination interview were scrutinized". The Description usually requires several sentences and, depending on the procedure, may include the specification of lengthy algorithm.
End-points covered through the follow-up
- All deaths:
- Specification of the cause:
- Non-fatal acute coronary events:
- Cognitive impairment/dementia:
ICD-version used for classification of diseases in the data
- Which version was used (if several, specify years and/or data sources for each):
References
Beulens JW, Monninkhof EM, Verschuren WM, van der Schouw YT, Smit J, Ocke MC, Jansen EH, van Dieren S, Grobbee DE, Peeters PH, Bueno-de-Mesquita HB. Cohort profile: the EPIC-NL study. Int J Epidemiol. 2010 Oct;39(5):1170-8. Epub 2009 May 29.
Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol. 2008 Dec;37(6):1236-41. Epub 2008 Jan 31.
|
